News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2011 Archives

Dec 13, 2011
NKTR-181 Exhibits Sustained and Dose-Dependent Analgesic Effect, Reduced Rate of Entry into the CNS and Wide Therapeutic Window

Nektar Therapeutics (Nasdaq: NKTR) today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in...

More
Dec 12, 2011
Study Design Highlighted at 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in Trials in Progress Session

Nektar Therapeutics (Nasdaq: NKTR) announced today that the company has initiated its pivotal Phase 3 global clinical trial evaluating NKTR-102 as a single agent in women with metastatic breast...

More
Dec 8, 2011

Nektar Therapeutics (NASDAQ:NKTR) today reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1,...

More
Nov 15, 2011
New Preclinical Studies for NKTR-102 Presented at 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Nektar Therapeutics (NASDAQ:NKTR) today presented positive preclinical data for NKTR-102, a next-generation topoisomerase I inhibitor, at the 2011 AACR-NCI-EORTC International Conference on...

More
Nov 14, 2011
NKTR-192 Demonstrates Rapid Onset of Analgesia, Slow Uptake into the Brain, Reduced Abuse Liability and Less Sedation Compared to Standard Opioid Therapies

Nektar Therapeutics (NASDAQ: NKTR) announced today that positive preclinical data for NKTR-192, a novel mu-opioid agonist, was presented at the 41st Annual Meeting of the Society for Neuroscience...

More
Nov 2, 2011

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2011. Cash, cash equivalents, and investments at September 30, 2011 were $458.0...

More
Oct 26, 2011

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2011 on Wednesday, November 2, 2011, after the close of U.S.-based financial...

More
Sep 21, 2011
NKTR-181 Exhibits Dose-Dependent Analgesic Response, Reduced Rate of Entry into the CNS and Extended Pharmacokinetic Profile

Nektar Therapeutics (NASDAQ:NKTR) today announced that positive proof-of-concept data is being presented from its first Phase 1 clinical trial of NKTR-181 at the American Academy of Pain...

More
Sep 14, 2011

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2011 Global Life Sciences Conference in New York at the...

More
Sep 9, 2011
NKTR-102 Phase 3 BEACON Clinical Trial Design Highlighted in Presentation

Nektar Therapeutics (Nasdaq: NKTR) announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO...

More
Sep 8, 2011

Nektar Therapeutics (Nasdaq: NKTR) today announced that dosing began in a Phase 1 clinical study to evaluate multiple ascending doses of NKTR-181, the company's novel opioid analgesic drug...

More
Aug 4, 2011

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2011. Cash, cash equivalents, and investments at June 30, 2011 were $481.8 million as...

More
Jul 27, 2011

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, August 4, 2011, after the close of U.S.-based financial markets....

More
Jul 18, 2011

Nektar Therapeutics (Nasdaq: NKTR) today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on its application for orphan...

More
Jun 7, 2011
Interim data analysis shows NKTR-181 achieved long-acting PK profile with analgesic response and excellent safety profile

Nektar Therapeutics (NASDAQ:NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate....

More
Jun 5, 2011
Phase 2 Data Highlighted in Presentation at 2011 American Society of Clinical Oncology Annual Meeting

Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a subpopulation of patients in a Phase 2 clinical study evaluating single-agent NKTR-102 in women with...

More
Jun 4, 2011
High rate of confirmed response maintained in poor prognosis and heavily pre-treated patients including those with visceral disease

Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic...

More
Jun 1, 2011

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2011 Global Healthcare Conference at The Grand Hyatt New York...

More
May 18, 2011

Nektar Therapeutics (Nasdaq: NKTR) today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected...

More
Apr 27, 2011

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the quarter ended March 31, 2011. Cash, cash equivalents, and short-term investments at March 31, 2011 were $518.6...

More
Apr 21, 2011

Nektar Therapeutics (Nasdaq: NKTR) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug status for the treatment of women with ovarian cancer by the...

More
Apr 18, 2011

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after the close of U.S.-based financial markets....

More
Mar 21, 2011

Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic...

More
Mar 15, 2011

AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of...

More
Mar 1, 2011

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2010. Cash, cash equivalents, and short-term investments at December 31,...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide